CAMBRIDGE, Mass., Sept. 20, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced results from the ongoing ARROW clinical trial showing durable responses and a well-tolerated safety profile for GAVRETO™ (pralsetinib) in patients with advanced RET-mutant medullary thyroid cancer (MTC). In these registrational data, GAVRETO demonstrated consistent clinical activity in patients across lines of therapy and regardless of RET mutation genotypes, including a high response rate in patients with gatekeeper mutations resistant to multi-kinase inhibitors. The results are being presented today in a proffered paper session during the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Enforcement Report - Week of August 29, 2018
Enforcement Report - Week of August 1, 2018
NEW DELHI: Drug firm StridesBSE 1.86 % Shasun today said its arm Arrow Pharmaceuticals has acquired Australian operations of Amneal Pharmaceuticals for a total consideration of AUD 17 million (over Rs 85 crore).
Patients are again being warned not to take their valium tablets after a second pharmaceutical company recalled the medication over evidence of drug tampering.